Cargando…

A Narrative Review of STAT Proteins in Diabetic Retinopathy: From Mechanisms to Therapeutic Prospects

Diabetic retinopathy (DR), a blinding disease, is one of the high-incidence chronic complications of diabetes. However, the current treatment for DR is mainly based on advanced pathological changes, which cannot reverse pre-existing retinal tissue damage and visual impairment. Signal transducer and...

Descripción completa

Detalles Bibliográficos
Autores principales: Hong, Libing, Lin, Yongqi, Yang, Xiongyi, Wu, Tong, Zhang, Yuxi, Xie, Zhuohang, Yu, Jieli, Zhao, Hejia, Yi, Guoguo, Fu, Min
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9547576/
https://www.ncbi.nlm.nih.gov/pubmed/36208390
http://dx.doi.org/10.1007/s40123-022-00581-0
_version_ 1784805294196391936
author Hong, Libing
Lin, Yongqi
Yang, Xiongyi
Wu, Tong
Zhang, Yuxi
Xie, Zhuohang
Yu, Jieli
Zhao, Hejia
Yi, Guoguo
Fu, Min
author_facet Hong, Libing
Lin, Yongqi
Yang, Xiongyi
Wu, Tong
Zhang, Yuxi
Xie, Zhuohang
Yu, Jieli
Zhao, Hejia
Yi, Guoguo
Fu, Min
author_sort Hong, Libing
collection PubMed
description Diabetic retinopathy (DR), a blinding disease, is one of the high-incidence chronic complications of diabetes. However, the current treatment for DR is mainly based on advanced pathological changes, which cannot reverse pre-existing retinal tissue damage and visual impairment. Signal transducer and activator of transcription (STAT) proteins are essential in DR through early and late stages. They participate in the early stage of DR through multiple mechanisms and have a strong proangiogenic effect in the late stage. Inhibiting STAT proteins activity has also achieved a significant effect in reversing the pathological changes of DR. Thus, STAT proteins are expected to be an effective therapeutic target in the early stage of DR and can make up for inadequate late treatment. This review introduces the structure, signal transduction mode, and biological functions of STAT proteins in detail and focuses on their role in the mechanism of DR. We also summarize the current research on STAT-related biological agents in DR, aiming to provide a theoretical basis for the treatment of DR.
format Online
Article
Text
id pubmed-9547576
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-95475762022-10-11 A Narrative Review of STAT Proteins in Diabetic Retinopathy: From Mechanisms to Therapeutic Prospects Hong, Libing Lin, Yongqi Yang, Xiongyi Wu, Tong Zhang, Yuxi Xie, Zhuohang Yu, Jieli Zhao, Hejia Yi, Guoguo Fu, Min Ophthalmol Ther Review Diabetic retinopathy (DR), a blinding disease, is one of the high-incidence chronic complications of diabetes. However, the current treatment for DR is mainly based on advanced pathological changes, which cannot reverse pre-existing retinal tissue damage and visual impairment. Signal transducer and activator of transcription (STAT) proteins are essential in DR through early and late stages. They participate in the early stage of DR through multiple mechanisms and have a strong proangiogenic effect in the late stage. Inhibiting STAT proteins activity has also achieved a significant effect in reversing the pathological changes of DR. Thus, STAT proteins are expected to be an effective therapeutic target in the early stage of DR and can make up for inadequate late treatment. This review introduces the structure, signal transduction mode, and biological functions of STAT proteins in detail and focuses on their role in the mechanism of DR. We also summarize the current research on STAT-related biological agents in DR, aiming to provide a theoretical basis for the treatment of DR. Springer Healthcare 2022-10-08 2022-12 /pmc/articles/PMC9547576/ /pubmed/36208390 http://dx.doi.org/10.1007/s40123-022-00581-0 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Review
Hong, Libing
Lin, Yongqi
Yang, Xiongyi
Wu, Tong
Zhang, Yuxi
Xie, Zhuohang
Yu, Jieli
Zhao, Hejia
Yi, Guoguo
Fu, Min
A Narrative Review of STAT Proteins in Diabetic Retinopathy: From Mechanisms to Therapeutic Prospects
title A Narrative Review of STAT Proteins in Diabetic Retinopathy: From Mechanisms to Therapeutic Prospects
title_full A Narrative Review of STAT Proteins in Diabetic Retinopathy: From Mechanisms to Therapeutic Prospects
title_fullStr A Narrative Review of STAT Proteins in Diabetic Retinopathy: From Mechanisms to Therapeutic Prospects
title_full_unstemmed A Narrative Review of STAT Proteins in Diabetic Retinopathy: From Mechanisms to Therapeutic Prospects
title_short A Narrative Review of STAT Proteins in Diabetic Retinopathy: From Mechanisms to Therapeutic Prospects
title_sort narrative review of stat proteins in diabetic retinopathy: from mechanisms to therapeutic prospects
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9547576/
https://www.ncbi.nlm.nih.gov/pubmed/36208390
http://dx.doi.org/10.1007/s40123-022-00581-0
work_keys_str_mv AT honglibing anarrativereviewofstatproteinsindiabeticretinopathyfrommechanismstotherapeuticprospects
AT linyongqi anarrativereviewofstatproteinsindiabeticretinopathyfrommechanismstotherapeuticprospects
AT yangxiongyi anarrativereviewofstatproteinsindiabeticretinopathyfrommechanismstotherapeuticprospects
AT wutong anarrativereviewofstatproteinsindiabeticretinopathyfrommechanismstotherapeuticprospects
AT zhangyuxi anarrativereviewofstatproteinsindiabeticretinopathyfrommechanismstotherapeuticprospects
AT xiezhuohang anarrativereviewofstatproteinsindiabeticretinopathyfrommechanismstotherapeuticprospects
AT yujieli anarrativereviewofstatproteinsindiabeticretinopathyfrommechanismstotherapeuticprospects
AT zhaohejia anarrativereviewofstatproteinsindiabeticretinopathyfrommechanismstotherapeuticprospects
AT yiguoguo anarrativereviewofstatproteinsindiabeticretinopathyfrommechanismstotherapeuticprospects
AT fumin anarrativereviewofstatproteinsindiabeticretinopathyfrommechanismstotherapeuticprospects
AT honglibing narrativereviewofstatproteinsindiabeticretinopathyfrommechanismstotherapeuticprospects
AT linyongqi narrativereviewofstatproteinsindiabeticretinopathyfrommechanismstotherapeuticprospects
AT yangxiongyi narrativereviewofstatproteinsindiabeticretinopathyfrommechanismstotherapeuticprospects
AT wutong narrativereviewofstatproteinsindiabeticretinopathyfrommechanismstotherapeuticprospects
AT zhangyuxi narrativereviewofstatproteinsindiabeticretinopathyfrommechanismstotherapeuticprospects
AT xiezhuohang narrativereviewofstatproteinsindiabeticretinopathyfrommechanismstotherapeuticprospects
AT yujieli narrativereviewofstatproteinsindiabeticretinopathyfrommechanismstotherapeuticprospects
AT zhaohejia narrativereviewofstatproteinsindiabeticretinopathyfrommechanismstotherapeuticprospects
AT yiguoguo narrativereviewofstatproteinsindiabeticretinopathyfrommechanismstotherapeuticprospects
AT fumin narrativereviewofstatproteinsindiabeticretinopathyfrommechanismstotherapeuticprospects